Zevra Therapeutics presents positive new real-world data on Miplyffa (arimoclomol) in patients with Neimann-Pick Disease Type C at the 22nd Annual WORLDSymposium
Zevra Therapeutics announced the presentation of four posters highlighting positive new data on Miplyffa (arimoclomol) for the treatment of Niemann-Pick Disease Type C (NPC) at the 22nd Annual… read more.

